Compare Quantum Computing Inc (QUBT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantum Computing Inc vs Tango Therapeutics Inc. — how do they compare? Quantum Computing Inc trades at $6.23 (market cap $1.56B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 2.4× Quantum Computing Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Quantum Computing Inc for 26 Days and Tango Therapeutics Inc. for 0 Days on average.
| QUBT | TNGX | |
|---|---|---|
Market Cap | $1.56B | $3.75B |
Volume | 6,616,227 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $21.23 | $32.90 |
52-Week Low | $6.31 | $7.50 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $621.96M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $6.87, down 0.87% on the day, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and cash burn persist.
While analyst consensus is bullish with a $17.33 price target (75% buy ratings), QUBT faces significant execution risks as it scales quantum hardware production. The stock offers substantial upside potential if commercialization succeeds but carries high volatility given pre-profitability status and competitive quantum computing landscape.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
